- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05628363
Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Hiram Gay, M.D.
- Phone Number: 314-362-8502
- Email: hiramgay@wustl.edu
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
Sub-Investigator:
- Eric Laugeman, M.S.
-
Sub-Investigator:
- Jeff Michalski, M.D., MBA, FASTRO
-
Contact:
- Hiram Gay, M.D.
- Phone Number: 314-362-8502
- Email: hiramgay@wustl.edu
-
Principal Investigator:
- Hiram Gay, M.D.
-
Sub-Investigator:
- Yi Huang, M.S.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Pathologically proven adenocarcinoma of the prostate with NCCN high-risk disease or NCCN unfavorable intermediate-risk disease.
Patients with unfavorable intermediate-risk disease must meet the following criteria:
At least one intermediate risk factor (IRF):
- PSA 10-20 ng/mL
- cT2b-c (AJCC 8th ed.)
- Gleason score 7
At least one "unfavorable" intermediate-risk identifier:
- > 1 IRF
- Gleason score 4+3
- ≥ 50% of biopsy cores positive
- NO high-risk features
- Predicted risk of lymph node involvement ≥ 10% using the Memorial Sloan-Kettering prostate cancer nomogram
Patients with high-risk disease must meet at least one of the following criteria:
- cT3a-T3b
- PSA > 20
- Gleason score ≥ 8
- 3T MRI scan of the prostate with at least one MR-detectable PIRADS 3 lesion in the prostate/seminal vesicles. PET/CT which is found to display activity n the prostate consistent with prostate cancer may be substituted per investigator discretion.
- Planning to undergo concurrent whole-pelvis SBRT and androgen deprivation therapy (ADT). ADT may be initiated at any time per institutional standard, so long as ADT begins within 60 days of the start of radiotherapy.
- At least 18 years of age.
- ECOG performance status ≤ 1
- Agreement to adhere to Lifestyle Considerations throughout study duration
- Able to complete relevant patient-reported quality-of-life questionnaires in the opinion of the treating physician.
- Able to understand and willing to sign an IRB approved written informed consent document.
Exclusion Criteria:
- Definitive radiologic evidence of nodal (cN+) or metastatic (cM1) disease on conventional imaging (bone scan) or prostate cancer-specific PET/CT scan (NaF PET/CT, Axumin PET/CT, fluciclovine, choline, or PSMA PET/CT scan). Patients with lymph nodes ≥ 1 cm on short axis are ineligible unless the lymph node is read as benign by Radiology.
- Prior androgen deprivation therapy. (If the onset of androgen ablation is ≤ 60 days prior to treatment start, the patient is eligible.) Baseline PSA and testosterone must be obtained prior to start of treatment.
- Systemic chemotherapy within 3 years prior to treatment start.
- Prior radical prostatectomy, pelvic lymph node dissection, prostate cryotherapy, or high-intensity focused ultrasound (HIFU) to the prostate.
- Prior pelvic radiotherapy.
- Presence of baseline CTCAE grade ≥ 2 GI or GU toxicity that does not resolve to grade 1 or less with appropriate intervention.
- cT4 disease.
- American Urologic Association (AUA) urinary symptom score ≥ 20
- Prostate gland measuring >90 cc.
- Unable to get prostate fiducial markers placed for image guided radiation treatment. Rectal hydrogel is optional and is left to the discretion of the treating physician.
- Patients with only PIRADS score of 3 lesions and no MR-fusion biopsy pathologic correlation.
- Hip prosthetic.
- Prior malignancy (except for non-melanoma skin cancer) unless disease-free for at least 2 years. Patients are not eligible if they have had a prior pelvic malignancy (e.g. bladder cancer, rectal cancer).
- Prior transurethral resection of the prostate (TURP) within 3 months prior to registration.
- Uncontrolled intercurrent illness precluding RT and/or ADT including, but not limited to, seizures, myocardial infarction in the past 6 months, current severe or unstable angina pectoris, congestive heart failure requiring hospitalization in the past 6 months, uncontrolled active infection, uncontrolled hypertension, or any condition that in the opinion of the investigator would preclude participation in the study.
- History of inflammatory bowel disease, including ulcerative colitis and Crohn's disease.
- Presence of anal fissure or history of bowel or bladder fistula.
- Scleroderma. Patients who are moderately symptomatic from other autoimmune diseases or patients on biologic therapies for autoimmune diseases are also excluded.
- Known history of HIV or chronic hepatitis B or C. Testing to evaluate for the presence of HIV and/or hepatitis B or C is not required in patients who do not carry the diagnosis.
- Poorly visualized bladder and bowel on diagnostic CT or CT simulation (either due to body habitus or artifact).
- Unable to spend 30 minutes lying on the radiation therapy treatment couch due to significant urinary frequency/urgency or other comorbidities.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Adaptive stereotactic body radiotherapy (SBRT)
|
Device that will be used to administer radiotherapy
Radiotherapy interruptions are acceptable as long as treatments are no more than 16 days apart.
Other Names:
Androgen deprivation therapy (ADT) will be administered to study patients according to institutional standard. Patients should initiate ADT beginning no sooner than 60 days prior to start of radiation. ADT is defined as a GnRH agonist/antagonist (leuprolide, goserelin, degarelix, or relugolix). Patients treated with leuprolide, goserelin, or degarelix should also receive an androgen receptor antagonist (flutamide or bicalutamide) for 30 days from the start of GnRH agonist/antagonist or until the end of radiation, depending on institutional standard and physician preference. Agent selection is per treating physician discretion and will be administered per institutional standard and FDA-approved labeling.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of acute grade ≥3 GI and GU adverse events
Time Frame: From start of radiotherapy through 90 days after start of radiotherapy
|
From start of radiotherapy through 90 days after start of radiotherapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in patient-reported quality of life as measured by EPIC-26
Time Frame: At screening, end of radiotherapy (week 5), 3 months after start of radiotherapy, and every 3 months until month 24
|
-The EPIC-26 is used to assess health related quality of life among persons with prostate cancer.
It contains 5 domains of urinary incontinence, urinary irritability/obstructive, bowel, sexual, and hormonal.
Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing better health related quality of life.
|
At screening, end of radiotherapy (week 5), 3 months after start of radiotherapy, and every 3 months until month 24
|
Changes in global function as measured by EQ-5D-5L
Time Frame: At screening, end of radiotherapy (week 5), 3 months after start of radiotherapy, and every 3 months until month 24
|
-The EQ-5D-5L is a commonly used and reliable questionnaire used to assess patient perception of their current health state.
Patients are asked about their levels of difficulty with mobility, self-care, and usual activities, and about their pain/discomfort and anxiety/depression levels on a 5-point scale where the response "I have no problems" = 1 and "I am unable/have extreme" = 5.
|
At screening, end of radiotherapy (week 5), 3 months after start of radiotherapy, and every 3 months until month 24
|
Rate of late GI and GU adverse events
Time Frame: From day 91 after the start of radiotherapy until completion of follow-up at month 60
|
From day 91 after the start of radiotherapy until completion of follow-up at month 60
|
|
Rate of acute grade ≥3 adverse events at least possibly related to radiotherapy
Time Frame: From start of radiotherapy through 90 days after start of radiotherapy
|
From start of radiotherapy through 90 days after start of radiotherapy
|
|
Rate of acute <grade 3 GI and GU adverse events
Time Frame: From start of radiotherapy through 90 days after start of radiotherapy
|
From start of radiotherapy through 90 days after start of radiotherapy
|
|
Rate of late grade ≥3 adverse events at least possibly related to radiotherapy
Time Frame: From day 91 after the start of radiotherapy until completion of follow-up at month 60
|
From day 91 after the start of radiotherapy until completion of follow-up at month 60
|
|
Failure-free survival
Time Frame: From start of radiotherapy until completion of follow-up (estimated to be 60 months)
|
-Time from start of radiotherapy to biochemical relapse, radiographic recurrence with development of local, regional or distant metastases, or death to due to any cause
|
From start of radiotherapy until completion of follow-up (estimated to be 60 months)
|
Biochemical recurrence free-survival
Time Frame: From start of radiotherapy until completion of follow-up (estimated to be 60 months)
|
|
From start of radiotherapy until completion of follow-up (estimated to be 60 months)
|
Metastasis-free survival
Time Frame: From start of radiotherapy until completion of follow-up (estimated to be 60 months)
|
-Time from start of radiotherapy treatment to radiographic diagnosis of metastatic disease (M1 disease) or death from any cause
|
From start of radiotherapy until completion of follow-up (estimated to be 60 months)
|
Prostate cancer-specific mortality
Time Frame: From start of radiotherapy until completion of follow-up (estimated to be 60 months)
|
-Time from start of radiotherapy to death due to prostate cancer.
|
From start of radiotherapy until completion of follow-up (estimated to be 60 months)
|
Overall survival
Time Frame: From start of radiotherapy until completion of follow-up (estimated to be 60 months)
|
-Time from start of radiotherapy to death from any cause
|
From start of radiotherapy until completion of follow-up (estimated to be 60 months)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Hiram Gay, M.D., Washington University School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Androgens
Other Study ID Numbers
- 202211121
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Ethos Varian treatment system
-
Varian, a Siemens Healthineers CompanyRigshospitalet, Denmark; Herlev HospitalRecruitingMuscle-Invasive Bladder CarcinomaDenmark
-
Varian, a Siemens Healthineers CompanyRecruitingCervical Cancer by FIGO Stage 2018United States
-
Herlev HospitalRecruitingAnal Squamous Cell Carcinoma | Anal Cancer | Anal CarcinomaDenmark
-
Institut du Cancer de Montpellier - Val d'AurelleNot yet recruiting
-
Turku University HospitalUnknownBone Cancer | Bone Metastases | Bone Neoplasm | Bone Lesion
-
Stanford UniversityCompletedLung CancerUnited States
-
Universidad Complutense de MadridRecruitingMalocclusion, Angle Class II | DistalizationSpain